Omeros stock climbed 17.1% in pre-open trading after the Seattle-based biopharmaceutical company released second-quarter 2026 results that outpaced Wall Street expectations on the top and bottom lines. Adjusted earnings per share came in at $0.02, compared with the consensus forecast of a $0.25 loss, while reported revenue reached $28.5 million versus analysts' $12.67 million estimate.
The standout contributor to the quarterly outperformance was YARTEMLEA, the company's FDA-approved lectin pathway complement inhibitor indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy. YARTEMLEA produced $32.2 million in gross product sales during Q2, a sequential rise of 190% from Q1's $11.1 million. Net revenue for the quarter totaled $28.5 million, representing an increase of 188% from the prior quarter's $9.9 million.
Beyond the revenue surprise, Omeros reported GAAP net income of $13.2 million, or $0.18 per share, and recorded positive operating cash flow for the first time in its recent history. Those milestones helped shift investor perception about the durability of the company's commercial trajectory and underpinned the pre-market rally.
Management highlighted ongoing reimbursement tailwinds as a meaningful factor supporting the commercial rollout, including a permanent CMS J-code assigned to YARTEMLEA. The company is also actively lowering its convertible debt load, a capital structure move that market participants cited as adding credibility to the growth story.
The broader market provided a modestly constructive backdrop for risk assets, with the S&P 500 up 0.2%, the Dow Jones up 0.2%, and the NASDAQ edging higher by 0.1% - moves that alone do not account for the magnitude of OMER's pre-market advance. The stock's pre-market price of $16.06 placed it close to its 52-week high of $17.65 and significantly above the 52-week low of $3.94, highlighting how investor sentiment has shifted in a short period.
Taken together, the quarterly revenue upside, the company's first reported GAAP profit, and a move into positive operating cash flow combined to produce one of the largest single-session gains in Omeros' recent trading history. Investors who had anticipated stronger commercial traction for YARTEMLEA were rewarded, while the scale of the outperformance surprised the wider market.
What this means for the company and markets
- YARTEMLEA's accelerated sales materially improved Omeros' revenue profile, shifting the business toward a commercially driven story.
- Crossing into GAAP profitability and positive operating cash flow provides a new set of financial metrics for investors to evaluate future performance.
- Reimbursement developments, such as the permanent CMS J-code, and debt reduction efforts can affect access and capital flexibility, respectively.
These results primarily affect the biotech and broader healthcare sector, with secondary relevance for equity markets given the size of the move in OMER's share price.